300363 Stock Overview
Engages in the manufacture and sale of small molecule active pharmaceutical ingredients, dosage forms, and biologics to the pharmaceutical companies in China, the United States, and Europe. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Porton Pharma Solutions Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥17.19 |
| 52 Week High | CN¥29.50 |
| 52 Week Low | CN¥10.91 |
| Beta | 0.21 |
| 11 Month Change | -8.12% |
| 3 Month Change | 43.97% |
| 1 Year Change | -40.54% |
| 33 Year Change | -82.24% |
| 5 Year Change | 28.19% |
| Change since IPO | -20.27% |
Recent News & Updates
Recent updates
Shareholder Returns
| 300363 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -5.3% | -1.8% | -2.6% |
| 1Y | -40.5% | -7.0% | 4.2% |
Return vs Industry: 300363 underperformed the CN Pharmaceuticals industry which returned -6% over the past year.
Return vs Market: 300363 underperformed the CN Market which returned 4.6% over the past year.
Price Volatility
| 300363 volatility | |
|---|---|
| 300363 Average Weekly Movement | 13.0% |
| Pharmaceuticals Industry Average Movement | 7.3% |
| Market Average Movement | 8.4% |
| 10% most volatile stocks in CN Market | 12.7% |
| 10% least volatile stocks in CN Market | 5.6% |
Stable Share Price: 300363's share price has been volatile over the past 3 months compared to the CN market.
Volatility Over Time: 300363's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of CN stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 4,300 | Nianfeng Ju | www.porton.cn |
Porton Pharma Solutions Ltd. engages in the manufacture and sale of small molecule active pharmaceutical ingredients, dosage forms, and biologics to the pharmaceutical companies in China, the United States, and Europe. The company was formerly known as Porton Fine Chemicals Ltd. and changed its name to Porton Pharma Solutions Ltd.
Porton Pharma Solutions Ltd. Fundamentals Summary
| 300363 fundamental statistics | |
|---|---|
| Market cap | CN¥9.38b |
| Earnings (TTM) | -CN¥391.43m |
| Revenue (TTM) | CN¥2.76b |
3.4x
P/S Ratio-24.0x
P/E RatioIs 300363 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 300363 income statement (TTM) | |
|---|---|
| Revenue | CN¥2.76b |
| Cost of Revenue | CN¥2.22b |
| Gross Profit | CN¥534.89m |
| Other Expenses | CN¥926.32m |
| Earnings | -CN¥391.43m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.72 |
| Gross Margin | 19.41% |
| Net Profit Margin | -14.20% |
| Debt/Equity Ratio | 24.7% |
How did 300363 perform over the long term?
See historical performance and comparison